Vista Oncology is currently participating in the following clinical trials:
A Study of Ramucirumab (LY3009806) in Combination with Paclitaxel in Participants with Gastric Cancer
ClinicalTrials.gov Identifier: NCT02514551
Purpose: Phase II trial for participants with second-line metastatic or locally advanced, unresectable gastric or gastroesophageal junction adenocarcinoma aims to evaluate the efficacy of an alternative dose of ramucirumab, in combination with paclitaxel. For inclusion and exclusion criteria and more information, visit the ClinicalTrials.gov page.
A Study of Abemaciclib (LY2835219) in Participants with Stage IV Squamous Non-small Cell Lung Cancer
ClinicalTrials.gov Identifier: NCT02450539
Purpose: Phase II trial for patients with stage IV squamous non-small cell lung cancer that has been previously treated with platinum-based chemotherapy aims to evaluate abemaciclib vs. docetaxel. For inclusion and exclusion criteria and more information, visit the ClinicalTrials.gov page.
A Phase III Randomized Double-Blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
ClinicalTrials.gov Identifier: NCT02437318
Purpose: To determine whether treatment with alpelisib plus fulvestrant prolongs progression-free survival compared to fulvestrant and placebo in men and postmenopausal women with hormone receptor positive (HR+), HER2-negative advanced breast cancer, who received prior treatment with an Aromatase Inhibitor either as (neo)adjuvant or for advanced disease. For inclusion and exclusion criteria and more information, visit the ClinicalTrials.gov page.
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 8 – LEE011 for Patients With CDK4/6 Pathway Activated Tumors
ClinicalTrials.gov Identifier: NCT02187783
Purpose: The purpose of this signal seeking study is to determine whether treatment with LEE011 demonstrates sufficient efficacy in CDK4/6 pathway activated solid tumors and/or hematologic malignancies to warrant further study.